Interaction of Histologic Subtype and Histologic Grade in Predicting Survival for Soft-Tissue Sarcomas

被引:57
作者
Canter, Robert J. [1 ]
Beal, Shannon [1 ]
Borys, Dariusz [2 ]
Martinez, Steve R. [1 ]
Bold, Richard J. [1 ]
Robbins, Anthony S. [3 ]
机构
[1] Univ Calif Davis, Div Surg Oncol, Ctr Canc, Sacramento, CA 95817 USA
[2] Univ Calif Davis Hlth Syst, Dept Pathol & Lab Med, Sacramento, CA USA
[3] Amer Canc Soc, Hlth Serv Res, Atlanta, GA 30329 USA
关键词
POSTOPERATIVE NOMOGRAM; PROGNOSTIC VARIABLES; FRENCH-FEDERATION; GROUP EXPERIENCE; CANCER REGISTRY; EXTREMITY; CENTERS; SYSTEM; REPRODUCIBILITY; LIPOSARCOMA;
D O I
10.1016/j.jamcollsurg.2009.10.007
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Histologic grade is considered the paramount prognostic factor in predicting survival for soft-tissue sarcomas (STS). Increasing data suggest that histologic type substantially impacts STS behavior. STUDY DESIGN: The Surveillance, Epidemiology, and End Results program was used to identify 17,364 cases of STS diagnosed between 1988 and 2004. Using death from STS as 1 of the outcomes variables, histologic types were grouped into 3 categories: favorable (survival >= 20% above the mean), neutral (survival within 20% of the mean), and unfavorable (survival >= 20% below the mean). The effect of histology on survival was analyzed stratified by tumor grade. Five-year survival was calculated using Kaplan-Meier analysis. RESULTS: Among 73 histologic types, malignant fibrous histiocytoma (24.1%); leiomyosarcoma, not otherwise specified (14.8%); sarcoma, not otherwise specified (12.8%); and myxoid liposarcoma (5.9%) were the most prevalent. Grade distribution was as follows: low, 12.6%; intermediate, 14.9%; high, 37.1%; and unknown, 35.4%. Risk of death from STS increased with increasing grade: 8.0% for low, 25.9% for intermediate, and 38.3% for high. Among low-grade tumors, risk of death from STS ranged from 4.3% for favorable types to 15.3% for unfavorable types. Among intermediate-grade tumors, risk of death from STS ranged from 6.0% for favorable types to 45.4% for unfavorable types. Among high-grade tumors, risk of death from STS ranged from 24.3% for favorable types to 58.9% for unfavorable types. CONCLUSIONS: Within categories of STS grade, there are substantial differences in survival, depending on histologic type. Histologic type is an important predictor of biologic behavior in STS. (J Am Coll Surg 2010;210:191-198. (C) 2010 by the American College of Surgeons)
引用
收藏
页码:191 / 198
页数:8
相关论文
共 35 条
[1]   PROGNOSIS IN HIGH-GRADE SOFT-TISSUE SARCOMAS - THE SCANDINAVIAN-SARCOMA-GROUP EXPERIENCE IN A RANDOMIZED ADJUVANT CHEMOTHERAPY TRIAL [J].
ALVEGARD, TA ;
BERG, NO ;
RANSTAM, J ;
RYDHOLM, A ;
ROOSER, B .
ACTA ORTHOPAEDICA SCANDINAVICA, 1989, 60 (05) :517-521
[2]   HISTOPATHOLOGY PEER-REVIEW OF HIGH-GRADE SOFT-TISSUE SARCOMA - THE SCANDINAVIAN-SARCOMA-GROUP EXPERIENCE [J].
ALVEGARD, TA ;
BERG, NO .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (12) :1845-1851
[3]   Impact of adjuvant radiation on survival: A note of caution when using cancer registry data to evaluate adjuvant treatments [J].
Bilimoria, Karl Y. ;
Stewart, Andrew K. ;
Tomlinson, James S. ;
Gay, E. Greer ;
Ko, Clifford Y. ;
Talamonti, Mark S. ;
Bentrem, David J. .
ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (12) :3321-3327
[4]  
Brennan M, 2005, Cancer: principles and practice of oncology, P1581
[5]   Why Do Patients with Low-Grade Soft Tissue Sarcoma Die? [J].
Canter, Robert J. ;
Qin, Li-Xuan ;
Ferrone, Cristina R. ;
Maki, Robert G. ;
Singer, Samuel ;
Brennan, Murray F. .
ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (12) :3550-3560
[6]  
CHANG HR, 1989, CANCER-AM CANCER SOC, V64, P1514, DOI 10.1002/1097-0142(19891001)64:7<1514::AID-CNCR2820640726>3.0.CO
[7]  
2-2
[8]  
COINDRE JM, 1986, CANCER-AM CANCER SOC, V58, P306, DOI 10.1002/1097-0142(19860715)58:2<306::AID-CNCR2820580216>3.0.CO
[9]  
2-7
[10]   Prognostic factors in adult patients with locally controlled soft tissue sarcoma: A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group [J].
Coindre, JM ;
Terrier, P ;
Bui, NB ;
Bonichon, F ;
Collin, F ;
LeDoussal, V ;
Mandard, AM ;
Vilain, MO ;
Jacquemier, J ;
Duplay, H ;
Sastre, X ;
Barlier, C ;
HenryAmar, M ;
Lesech, JM ;
Contesso, G .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :869-877